Olympus Corp. (JP:7733)
:7733
7733 Stock Chart & Stats
¥1993.50
¥60.50(2.58%)
At close: 4:00 PM EST
¥1993.50
¥60.50(2.58%)
Day’s Range― - ―
52-Week Range¥1,302.50 - ¥2,168.00
Previous CloseN/A
Volume4.23M
Average Volume (3M)3.67M
Market Cap
¥1.58T
Enterprise Value¥1.68T
Total Cash (Recent Filing)¥196.74B
Total Debt (Recent Filing)¥237.82B
Price to Earnings (P/E)38.6
Beta0.79
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.01%
Share Statistics
EPS (TTM)12.87
Shares Outstanding1,114,485,700
10 Day Avg. Volume4,971,740
30 Day Avg. Volume3,665,053
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)2.96
Price to Sales (P/S)2.23
P/FCF Ratio15.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)57.22
Revenue Forecast (FY)¥996.63B
Bulls Say, Bears Say
Bulls Say
Margin SustainabilityHigh gross (~67%) and operating (~15%) margins reflect durable pricing power from capital equipment plus recurring consumables and services. These structural margins support long-term profitability, fund R&D and service networks, and provide resilience through product cycles.
Improving Balance SheetLeverage has meaningfully declined from prior peaks and equity remains sizeable, giving Olympus financial flexibility. Improved debt metrics and healthy ROE reduce refinancing and credit risk, enabling investment in remediation, capex, and strategic initiatives without overleveraging.
Structural Remediation & Leadership ActionsManagement has launched a formal QA/regulatory remediation, harmonized quality systems, appointed operations and tech leaders, and reaffirmed midterm growth and margin targets. These structural governance and process upgrades strengthen compliance and execution over the medium term.
Bears Say
Regulatory/Ship‑hold RiskActive FDA observations and remaining product remediations create ongoing market access and compliance risk. Prolonged holds or additional findings can limit product availability, raise remediation costs, and erode hospital trust, affecting revenue recovery over several quarters.
Variable Cash ConversionOperating and free cash flow have been inconsistent, with a notable FY2024 trough and a rebound thereafter. This variability reduces predictability for capital allocation, makes funding restructuring or R&D more sensitive to earnings swings, and could constrain long-term investment pacing.
Stalled Revenue & Commercial ExecutionRevenue growth has cooled and TTM sales are roughly flat, while management flagged U.S. GI execution issues and dependence on a nascent China rebound. Persistent sales execution gaps and regional volatility threaten sustainable top‑line expansion unless commercial effectiveness improves.
Olympus News
7733 FAQ
What was Olympus Corp.’s price range in the past 12 months?
Olympus Corp. lowest stock price was ¥1302.50 and its highest was ¥2168.00 in the past 12 months.
What is Olympus Corp.’s market cap?
Olympus Corp.’s market cap is ¥1.58T.
When is Olympus Corp.’s upcoming earnings report date?
Olympus Corp.’s upcoming earnings report date is Aug 12, 2026 which is in 137 days.
How were Olympus Corp.’s earnings last quarter?
Olympus Corp. released its earnings results on Feb 13, 2026. The company reported ¥12.87 earnings per share for the quarter, missing the consensus estimate of ¥23.057 by -¥10.187.
Is Olympus Corp. overvalued?
According to Wall Street analysts Olympus Corp.’s price is currently Overvalued.
Does Olympus Corp. pay dividends?
Olympus Corp. pays a Annually dividend of ¥30 which represents an annual dividend yield of 1.01%. See more information on Olympus Corp. dividends here
What is Olympus Corp.’s EPS estimate?
Olympus Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Olympus Corp. have?
Olympus Corp. has 1,114,485,700 shares outstanding.
What happened to Olympus Corp.’s price movement after its last earnings report?
Olympus Corp. reported an EPS of ¥12.87 in its last earnings report, missing expectations of ¥23.057. Following the earnings report the stock price went down -5.219%.
Which hedge fund is a major shareholder of Olympus Corp.?
Currently, no hedge funds are holding shares in JP:7733
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Olympus Corp.
Olympus Corporation manufactures and sells precision machineries and instruments worldwide. It operates through four segments: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, and Others. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopes, endoscopy system, and repair services. The Therapeutic Solutions Business segment provides urology, gynecology, ear, nose, and throat products; endo-therapy and energy devices; and surgical single-use devices. The Scientific Solutions Business segment offers biological and industrial microscopes, industrial endoscopes and videoscopes, non-destructive testing equipment, and X-ray fluorescence (XRF) analyzers. The Others segment offers biomedical materials and orthopedic equipment. The company also offers medical devices, such as surgical microscopes, endoscope reprocessors, electrosurgical devices, and respiratory-endotherapy devices, as well as system integration and maintenance/services. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was founded in 1919 and is headquartered in Tokyo, Japan.
7733 Company Deck
7733 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented a mix of significant near-term challenges—most notably product ship holds, FDA observations, one-off costs that reduced gross margin and a 2% revenue guidance downgrade—balanced against clear remediation plans, leadership actions, a majority of held products already released (70%), an asserted China recovery (≈5–6%), maintained midterm targets and a commitment to >100 bps margin expansion beginning FY2027. Near-term financial impact is material, but management articulated specific corrective actions and kept long-term targets unchanged.View all JP:7733 earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---